Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis

Autor: Carvelli, Julien, Demaria, Olivier, Vély, Frédéric, Batista, Luciana, Chouaki Benmansour, Nassima, Fares, Joanna, Carpentier, Sabrina, Thibult, Marie-Laure, Morel, Ariane, Remark, Romain, André, Pascale, Represa, Agnès, Piperoglou, Christelle, Assante Miranda, Laura, Baron, William, Belaid, Nourhène, Caillet, Clarisse, Caraguel, Flavien, Carrette, Barbara, Carrette, Florent, Chanuc, Fabien, Courtois, Rachel, Fenis, Aurore, Giordano, Marilyn, Girard-Madoux, Mathilde, Giraudon-Paoli, Marc, Gourdin, Nicolas, Grondin, Gwendoline, Guillot, Franceline, Habif, Guillaume, Jaubert, Solène, Lopez, Julie, Le Van, Mélanie, Lovera, Naouel, Mansuy, Marine, Bonnet, Elodie, Sansaloni, Audrey, Reboul, Annick, Mitry, Emmanuel, Nekkar-Constant, Camille, Péri, Valentine, Ricaut, Paul, Simon, Léa, Vallier, Jean-Baptiste, Vétizou, Marie, Zerbib, Robert, Ugolini, Sophie, Etiennot, Marion, Galluso, Justine, Lyonnet, Luc, Forel, Jean-Marie, Papazian, Laurent, Velly, Lionel, André, Baptiste, Briantais, Antoine, Faucher, Benoit, Jean, Estelle, Seguier, Julie, Veit, Veronique, Harlé, Jean-Robert, Pastorino, Boris, Delteil, Clémence, Daniel, Laurent, Boudsocq, Jean-Paul, Clerc, Axelle, Delmond, Emmanuel, Vidal, Pierre-Olivier, Savini, Hélène, Coutard, Bruno, Cordier, Pierre Yves, Le Dault, Erwan, Guervilly, Christophe, Simeone, Pierre, Gainnier, Marc, Morel, Yannis, Ebbo, Mikael, Schleinitz, Nicolas, Vivier, Eric

Publikováno v: Nature

Coronavirus disease 2019 (COVID-19) is a disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in a pandemic1. The C5a complement factor and its receptor C5aR1 (also known as CD88) have a key r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3c39cb09f9a23932a2a2ca8a45f40ab
https://doi.org/10.1038/s41586-020-2600-6

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma.

Autor: Demaria O; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Habif G; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Vetizou M; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Gauthier L; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Remark R; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Chiossone L; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Vagne C; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Rebuffet L; Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France., Courtois R; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Denis C; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Le Floch F; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Muller M; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Girard-Madoux M; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Augier S; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Lopez J; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Carrette B; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Maguer A; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Vallier JB; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Grondin G; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Baron W; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Galluso J; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Yessaad N; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Giordano M; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Simon L; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Chanuc F; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Alvarez AB; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Perrot I; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Bonnafous C; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Represa A; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Rossi B; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Morel A; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Morel Y; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Paturel C; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France., Vivier E; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France.; Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.; APHM, Hôpital de la Timone, Marseille-Immunopôle Profiling Platform, Marseille, France.; Paris-Saclay Cancer Cluster, Le Kremlin-Bicêtre, France.; Université Paris-Saclay, Gustave Roussy, INSERM, Prédicteurs moléculaires et nouvelles cibles en oncologie, 94800, Villejuif, France.

Publikováno v: Science immunology [Sci Immunol] 2024 Nov 15; Vol. 9 (101), pp. eadp3720. Date of Electronic Publication: 2024 Nov 15.